Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

Naval Daver, Aditi Shastri, Tapan Kadia, Kate Newberry, Naveen Pemmaraju, Elias Jabbour, Linghsa Zhou, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. <10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

Original languageEnglish (US)
Pages (from-to)1126-1129
Number of pages4
JournalLeukemia Research
Volume38
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Primary Myelofibrosis
Prednisone
Anemia
Fatigue
Hemoglobins
Blood Platelets
Spleen
pomalidomide
Therapeutics
Research

Keywords

  • Anemia
  • Myelofibrosis
  • Pomalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. / Daver, Naval; Shastri, Aditi; Kadia, Tapan; Newberry, Kate; Pemmaraju, Naveen; Jabbour, Elias; Zhou, Linghsa; Pierce, Sherry; Cortes, Jorge; Kantarjian, Hagop; Verstovsek, Srdan.

In: Leukemia Research, Vol. 38, No. 9, 2014, p. 1126-1129.

Research output: Contribution to journalArticle

Daver, N, Shastri, A, Kadia, T, Newberry, K, Pemmaraju, N, Jabbour, E, Zhou, L, Pierce, S, Cortes, J, Kantarjian, H & Verstovsek, S 2014, 'Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia', Leukemia Research, vol. 38, no. 9, pp. 1126-1129. https://doi.org/10.1016/j.leukres.2014.06.015
Daver, Naval ; Shastri, Aditi ; Kadia, Tapan ; Newberry, Kate ; Pemmaraju, Naveen ; Jabbour, Elias ; Zhou, Linghsa ; Pierce, Sherry ; Cortes, Jorge ; Kantarjian, Hagop ; Verstovsek, Srdan. / Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. In: Leukemia Research. 2014 ; Vol. 38, No. 9. pp. 1126-1129.
@article{d28406aa8c2548b39c8d18277a0f33ec,
title = "Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia",
abstract = "We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. <10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21{\%}) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.",
keywords = "Anemia, Myelofibrosis, Pomalidomide",
author = "Naval Daver and Aditi Shastri and Tapan Kadia and Kate Newberry and Naveen Pemmaraju and Elias Jabbour and Linghsa Zhou and Sherry Pierce and Jorge Cortes and Hagop Kantarjian and Srdan Verstovsek",
year = "2014",
doi = "10.1016/j.leukres.2014.06.015",
language = "English (US)",
volume = "38",
pages = "1126--1129",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia

AU - Daver, Naval

AU - Shastri, Aditi

AU - Kadia, Tapan

AU - Newberry, Kate

AU - Pemmaraju, Naveen

AU - Jabbour, Elias

AU - Zhou, Linghsa

AU - Pierce, Sherry

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2014

Y1 - 2014

N2 - We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. <10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

AB - We evaluated pomalidomide with prednisone for myelofibrosis (MF) with significant anemia (hemoglobin. <10. g/dL). Patients (n= 29; 18 RBC-transfusion dependent) received 0.5. mg pomalidomide daily in continuous 28-day cycles with prednisone given for the first 3 cycles only. Six (21%) patients responded (median response duration 11.4 months), including four who achieved RBC-transfusion-independence per the Delphi criteria and two who achieved clinical improvement (in platelets and spleen, respectively) per the International Working Group for Myelofibrosis Research and Treatment criteria. Grade 3 toxicity occurred in 1 patient (fatigue). Pomalidomide with prednisone is safe therapy with modest activity in patients with MF and anemia. ClinicalTrials.gov Identifier: NCT00946270.

KW - Anemia

KW - Myelofibrosis

KW - Pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=84906934354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906934354&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.06.015

DO - 10.1016/j.leukres.2014.06.015

M3 - Article

C2 - 25047979

AN - SCOPUS:84906934354

VL - 38

SP - 1126

EP - 1129

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -